Natcopharm share price

Natco Pharma Ltd.: Share Price, Stock Analysis, Annual Report | Value Research Natco Pharma Ltd.: Share Price, Stock Analysis, Annual Report | Value Research https://www.valueresearchonline.com/stocks/43459/natco-pharma-ltd/ Get Natco Pharma Ltd.'s stock analysis, price valuation, corporate actions, and financials from India's independent mutual fund research house. Business NATCO Pharma Limited, a pharmaceutical company, develops, manufactures, and markets finished dosage formulations and active pharmaceutical ingredients (APIs). It offers formulations in various therapeutic areas, including cancers of blood, liver, kidney, lung, brain, breast, ovary, etc.; and APIs in various categories, such as oncology, central nervous system, pain management, and CV care. The company also offers orthopedic products comprising bisphosphonates, which are oral and injectable drugs; and gastroenterology products consisting of novel drugs for chronic hepatitis-B and hepatitis-C, as well as contract manufacturing services. In addition, it provides cardiology and diabetology products for the treatment of hypertension, stable angina, and CHF; and agro chemicals and biological pest management solutions for management of insects, diseases, and weeds across a range of crops. The company markets its products in approximately 50 countries. NATCO Pharma Limited was incorporated in 1981 and is headquartered in Hyderabad, India.

Sales 2023 26844M 327M 327M Net income 2023 7188M 87,7M 87,7M Net Debt 2023 37,0M 0,45M 0,45M P/E ratio 2023 16,2x Yield 2023 1,14% Sales 2024 35523M 433M 433M Net income 2024 10882M 133M 133M Net Debt 2024 834M 10,2M 10,2M P/E ratio 2024 10,7x Yield 2024 1,44% Capitalization 115B 1397M 1397M EV / Sales 2023 4,27x EV / Sales 2024 3,25x Nbr of Employees 4 025 Free-Float 49,5% More Financials Company Natco Pharma Limited is an India-based vertically integrated, research and development (R&D)-focused pharmaceutical company. The Company is engaged in the business of pharmaceuticals, which comprises research and development, manufacturing and selling of bulk drugs and finished dosage formulations. The Company deals in the production of finished dosage formulations (FDF), which it sells in India, the United States...

• 12:37p Big stock market rally to be followed by ‘big collapse,’ says BofA’s Hartnett • 12:37p Barron's The Case for Selling Tech Stocks Like Nvidia, Microsoft • 12:15p Opinion Here’s a Father’s Day gift that dads can give to the whole family • 12:14p Lying about using and abusing money can be worse than the debt and losses • 12:13p Barron's Stocks Just Can't Compete With Bonds Right Now • 12:11p European stocks climb Friday • 12:07p Here’s a big reason you can expect bonds to start outperforming stocks • 12:01p U.K. stocks extend winning streak for fifth session • 12:01p ‘My daughter will be disappointed if I don’t take her to Taylor Swift’: White House targets junk fees — but why do we pay them? • 11:56a ‘It feels like a heavy burden’: My husband asked me to sell my $14,000 engagement ring to pay off our debt. Is he asking too much? • • to be replaced Key Data • Open ₹650.50 • Day Range 627.05 - 654.90 • 52 Week Range N/A • Market Cap N/A • Shares Outstanding 183.66M • Public Float 87.4M • Beta N/A • Rev. per Employee ₹4.836M • P/E Ratio N/A • EPS N/A • Yield N/A • Dividend N/A • Ex-Dividend Date N/A • Short Interest N/A • % of Float Shorted N/A • Average Volume N/A Natco Pharma Ltd. NATCO Pharma Ltd. engages in the business of pharmaceuticals with research, manufacturing and marketing of finished dosage formulations and active pharmaceutical ingredients. It operates through the following segments: Domestic Formulations, International Formulations, and Active Pharmaceut...

Return on average equity - 5 year average 12.39 Net Income/employee - trailing 12 month - Revenue/employee - most recent fiscal year - Return on investment - most recent fiscal year 15.26 Return on average assets - most recent fiscal year 13.29 Receivables turnover - most recent fiscal year 3.67 Return on investment - trailing 12 month 15.26 Return on average assets - trailing 12 month 13.29 Inventory turnover - most recent fiscal year 0.78 Inventory turnover - trailing 12 month 0.83 Revenue/employee - trailing 12 month - Return on average assets - 5 year average 10.34 Net Income/employee - most recent fiscal year - Return on average equity - trailing 12 month 15.66 Receivables turnover - trailing 12 month 3.67 Asset turnover - most recent fiscal year 0.50 Asset turnover - trailing 12 month 0.50 Return on average equity - most recent fiscal year 15.66 Return on investment - 5 year average 12.04

The Institutional Brokers' Estimate System (I/B/E/S) is a database of estimates made by stock analysts regarding the future earnings of publicly traded companies. It provides analyst forecasts on company performance expressed via various consensus measures, including earnings per share, sales, and net income. These estimates are aggregated by Refinitiv using it’s Institutional Brokers' Estimate System and displayed by us on “AS IS” basis. The estimates that are displayed should not be construed to be investment recommendation/advice or an offer or solicitation of an offer to buy/sell any securities by Nextbillion Technology Pvt Ltd (Groww). Investors should not solely rely on the information displayed herein and must make investment decisions based on their own investment objectives, judgment, risk profile, and financial position. Past performance should not be taken as an indication or guarantee of future performance. Kindly note that investment in securities markets is subject to market risks, read all the related documents carefully before investing. Natco Pharma Limited is an India-based vertically integrated, research and development (R&D)-focused pharmaceutical company. The Company is engaged in the business of pharmaceuticals, which comprises research and development, manufacturing and selling of bulk drugs and finished dosage formulations. The Company deals in the production of finished dosage formulations (FDF), which it sells in India, the United States and the R...

Return on average equity - 5 year average 12.39 Net Income/employee - trailing 12 month - Revenue/employee - most recent fiscal year - Return on investment - most recent fiscal year 15.26 Return on average assets - most recent fiscal year 13.29 Receivables turnover - most recent fiscal year 3.67 Return on investment - trailing 12 month 15.26 Return on average assets - trailing 12 month 13.29 Inventory turnover - most recent fiscal year 0.78 Inventory turnover - trailing 12 month 0.83 Revenue/employee - trailing 12 month - Return on average assets - 5 year average 10.34 Net Income/employee - most recent fiscal year - Return on average equity - trailing 12 month 15.66 Receivables turnover - trailing 12 month 3.67 Asset turnover - most recent fiscal year 0.50 Asset turnover - trailing 12 month 0.50 Return on average equity - most recent fiscal year 15.66 Return on investment - 5 year average 12.04

Natco Pharma Ltd.: Share Price, Stock Analysis, Annual Report | Value Research Natco Pharma Ltd.: Share Price, Stock Analysis, Annual Report | Value Research https://www.valueresearchonline.com/stocks/43459/natco-pharma-ltd/ Get Natco Pharma Ltd.'s stock analysis, price valuation, corporate actions, and financials from India's independent mutual fund research house. Business NATCO Pharma Limited, a pharmaceutical company, develops, manufactures, and markets finished dosage formulations and active pharmaceutical ingredients (APIs). It offers formulations in various therapeutic areas, including cancers of blood, liver, kidney, lung, brain, breast, ovary, etc.; and APIs in various categories, such as oncology, central nervous system, pain management, and CV care. The company also offers orthopedic products comprising bisphosphonates, which are oral and injectable drugs; and gastroenterology products consisting of novel drugs for chronic hepatitis-B and hepatitis-C, as well as contract manufacturing services. In addition, it provides cardiology and diabetology products for the treatment of hypertension, stable angina, and CHF; and agro chemicals and biological pest management solutions for management of insects, diseases, and weeds across a range of crops. The company markets its products in approximately 50 countries. NATCO Pharma Limited was incorporated in 1981 and is headquartered in Hyderabad, India.

• 5:02p Bristol Myers Squibb sues federal government over Medicare drug negotiations: report • 4:46p U.S. financial regulators say they’re tracking exposures to commercial real estate as vacancy rates rise, especially for office space • 4:45p Barron's AI Won't Kill the Music. Buy Stock in These 2 Labels. • 4:45p WeWork stockholders vote for reverse stock split • 4:44p U.S. stocks end lower, but S&P 500 scores longest weekly win streak since 2021 after Fed pause • 4:43p Barron's AutoNation Stock Has Rallied. CEO Michael Manley Scooped Up $1 Million of Shares • 4:41p Barron's How the World's Most Popular Shopping App Is Quietly Upending Retail • 4:41p Barron's It’s Everything Los Cabos, Mexico, Isn’t. Quiet, Remote, and Ripe for Exploring. • 4:39p Barron's NRG Takes a Stand Amid Fight With Activist Elliott • 4:36p Nvidia is the only near-term ‘beat and raise’ chip maker when it comes to AI, analyst says • • to be replaced Key Data • Open ₹650.50 • Day Range 627.05 - 654.90 • 52 Week Range N/A • Market Cap N/A • Shares Outstanding 183.66M • Public Float 87.4M • Beta N/A • Rev. per Employee ₹4.836M • P/E Ratio N/A • EPS N/A • Yield N/A • Dividend N/A • Ex-Dividend Date N/A • Short Interest N/A • % of Float Shorted N/A • Average Volume N/A Natco Pharma Ltd. NATCO Pharma Ltd. engages in the business of pharmaceuticals with research, manufacturing and marketing of finished dosage formulations and active pharmaceutical ingredients. It operates through the following segments: Domes...

Sales 2023 26844M 327M 327M Net income 2023 7188M 87,7M 87,7M Net Debt 2023 37,0M 0,45M 0,45M P/E ratio 2023 16,2x Yield 2023 1,14% Sales 2024 35523M 433M 433M Net income 2024 10882M 133M 133M Net Debt 2024 834M 10,2M 10,2M P/E ratio 2024 10,7x Yield 2024 1,44% Capitalization 115B 1397M 1397M EV / Sales 2023 4,27x EV / Sales 2024 3,25x Nbr of Employees 4 025 Free-Float 49,5% More Financials Company Natco Pharma Limited is an India-based vertically integrated, research and development (R&D)-focused pharmaceutical company. The Company is engaged in the business of pharmaceuticals, which comprises research and development, manufacturing and selling of bulk drugs and finished dosage formulations. The Company deals in the production of finished dosage formulations (FDF), which it sells in India, the United States...

The Institutional Brokers' Estimate System (I/B/E/S) is a database of estimates made by stock analysts regarding the future earnings of publicly traded companies. It provides analyst forecasts on company performance expressed via various consensus measures, including earnings per share, sales, and net income. These estimates are aggregated by Refinitiv using it’s Institutional Brokers' Estimate System and displayed by us on “AS IS” basis. The estimates that are displayed should not be construed to be investment recommendation/advice or an offer or solicitation of an offer to buy/sell any securities by Nextbillion Technology Pvt Ltd (Groww). Investors should not solely rely on the information displayed herein and must make investment decisions based on their own investment objectives, judgment, risk profile, and financial position. Past performance should not be taken as an indication or guarantee of future performance. Kindly note that investment in securities markets is subject to market risks, read all the related documents carefully before investing. Natco Pharma Limited is an India-based vertically integrated, research and development (R&D)-focused pharmaceutical company. The Company is engaged in the business of pharmaceuticals, which comprises research and development, manufacturing and selling of bulk drugs and finished dosage formulations. The Company deals in the production of finished dosage formulations (FDF), which it sells in India, the United States and the R...